In October 2017, Major National Science and Technology Achievement Transformation Fund (hereinafter referred to as "Major Special Fund") , managed by SDIC Venture Capital, accomplished a total investment of RMB260 million in Omni (Suzhou) Pharmaceutical Co., Ltd. (hereinafter referred to as Omni), which was jointly invested by Vivo Capital.

Respiratory drug delivery, for its high technical barriers, complex processing details, is recognized as the most complicated high-end preparations in the industry. Omni is a pharmaceutical company specializing in the research, development and production of respiratory drug delivery. Adhering to the "made in China and global sharing", Omni Pharmaceutical Co., Ltd. is committed to breaking the monopoly status of imported pharmaceutical products in the domestic market and providing world-class inhalation preparation. After 6 years of intensive research in the field of respiratory tract administration, Omni has achieved the R&D and production of four mainstream inhalation formulations of powder, aerosol, nasal spray and aerosol, and established a technology platform and production site in line with the international market standard. Dry powder preparation project has received major national special project support. The company also has an independent respiratory device research and development capabilities, which will improve patient compliance into product design. Company's products cover a wide range of respiratory drug delivery in the area, a number of research projects will begin this year and enter the clinical research phase.

At this stage, the overall manufacturing level of high-end inhalation formulations is weak in China. SDICVC, as the lead investor, will not only inject powerful promoters into its accumulated products to enable it to develop high-quality products as soon as possible, contributing to making up for shortages, meeting the needs of the masses and reducing medical expenses, and but also dramatically promote domestic high-end inhalation formulations R&D and manufacturing levels.